Of note, however, are a series of case reports, albeit limited, of patients with XP, which describe favorable responses, mostly in the clinical settings of metastatic melanoma and metastatic squamous cell carcinoma, following treatment with PD-1-targeted monoclonal antibodies, most commonly pembrolizumab (reviewed in 25, 26). Here, PDCD1 is linked to xeroderma pigmentosum.